US Patent

US8252331 — Osmotic device containing amantadine and an osmotic salt

Formulation · Assigned to Osmotica Kereskedelmi es Szolgaltato KFT · Expires 2030-03-13 · 4y remaining

Vulnerability score 48/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects an osmotic device containing a unitary core with a salt of amantadine and an osmotic salt to modify the release rate of amantadine.

USPTO Abstract

The osmotic devices of the present invention contain a unitary core comprising a salt of amantadine and an osmotic salt, wherein the two salts have an ion in common. The release rate of the amantadine is modified from a first order release profile to a zero order, pseudo-zero order or sigmoidal release profile by increasing the amount of the osmotic salt in the core of the device. The osmotic device includes a semipermeable membrane having a controlled porosity that can be adapted as needed to cooperate with the osmotic salt in providing a predetermined drug release profile. The osmotic salt need not be coated and it is in admixture with the amantadine salt.

Drugs covered by this patent

Patent Metadata

Patent number
US8252331
Jurisdiction
US
Classification
Formulation
Expires
2030-03-13
Drug substance claim
No
Drug product claim
Yes
Assignee
Osmotica Kereskedelmi es Szolgaltato KFT
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.